Targeting solid tumors with these cellular therapies has proven to be challenging, and there is significant room for progress in this area.
Targeting solid tumors with these cellular therapies has proven to be challenging, and there is significant room for progress in this area. We are keeping an eye on novel CAR T-cell therapies that are armored with additional mechanisms that have the potential to survive the defenses of tumors in the tumor microenvironment. In our view, recent preliminary data from T-cell receptor (TCR)-targeting modalities — in both soluble (TCR engagers) and cell therapy (TCR-Ts) formats — combined with proof-of-concept clinical data from public companies working on this modality show encouraging progress. As we continue to explore the space, we are excited by second-generation products being built by multiple private companies focused on this innovation.